Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 315
Filtrar
1.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 37(10): 634-641, dic. 2019. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-189589

RESUMO

INTRODUCCIÓN: Los circuitos de diagnóstico de la hepatitis C son complejos. El diagnóstico de infección activa en la misma muestra simplificaría el proceso estableciendo un acceso rápido al tratamiento. Nuestro objetivo fue estimar el impacto sanitario y económico del diagnóstico de la infección crónica en un solo paso (D1P) comparado con el diagnóstico tradicional (DTRA) en Andalucía (8,39 millones de personas). MÉTODOS: Se realizó un árbol de decisión para estimar la derivación de los pacientes con infección crónica, pérdidas de seguimiento, acceso al tratamiento y costes del diagnóstico de la infección, para ambos procesos. Los costes unitarios, en euros (€) de 2018, de los recursos sanitarios (visitas médicas, anticuerpos, carga viral y genotipo), sin considerar el coste farmacológico, se obtuvieron de fuentes públicas de Andalucía. RESULTADOS: del total de la población estimada (269.526 pacientes), 1.389 pacientes serían derivados al especialista en el D1P y 1.063 en el DTRA, siendo tratados 1.320 y 1.009, respectivamente. Con el D1P ningún paciente con carga viral negativa sería remitido al especialista, frente a los 540 con el DTRA. El D1P generaría un ahorro de costes de 184.928 € frente al DTRA (15.671.493 vs 15.856.421 €). Al comparar el D1P frente a DTRA, el ahorro por paciente con carga viral positiva derivado al especialista sería de 3.644 € (11.279 vs 14.923 €). CONCLUSIONES: El diagnóstico en un solo paso conseguirá un aumento de pacientes diagnosticados, aumentará el acceso de los pacientes crónicos al tratamiento y generará un ahorro de costes, demostrando su eficiencia en el sistema sanitario en Andalucía


BACKGROUND: The cascade of care of the hepatitisC are complex. The diagnosis of active infection in the same serum sample would simplify the process establishing a rapid access for patients to treatment. Our objective was to estimate the impact on healthcare and economic outcomes of the diagnosis of chronic infection in one-step diagnosis compared to standard diagnosis in Andalusia (8.39 million people). METHODS: A decision tree was developed to estimate the referral of patients with chronic infection, loss of follow-up, access to treatment and costs of the diagnosis of the infection, for both processes. The unit costs (€, 2018) of the health resources (medical visits, antibodies, viral load and genotype), without considering the pharmacological cost, were obtained form public sources in Andalusia. RESULTS: Of the total estimated population (269,526 patients), 1,389 patients would be referred to the specialised care in the one-step diagnosis and 1,063 in de standard diagnosis, being treated 1,320 and 1,009, respectively. In one-step diagnosis, no negative viral loud patient would be referred to specialist versus 540 with standard diagnosis. One-step diagnosis would generate a cost saving of €184,928 versus standard diagnosis (€15,671,493 vs €15,856,421). When compared one-step diagnosis to standard diagnosis, the savings per patient with positive viral load referred to specialist would be € 3,634 (€ 11,279 vs € 14,923). CONCLUSION: The one-step diagnosis will achieve an increase in diagnosed patients, will increase the access of chronic patient to treatment and will generate cost savings, demonstrating its efficiency in the system in Andalusia


Assuntos
Humanos , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/economia , Avaliação de Custo-Efetividade , Hepatite C Crônica/microbiologia , Avaliação em Saúde , Árvores de Decisões , Testes de Sensibilidade Microbiana/métodos , Testes de Sensibilidade Microbiana/economia
2.
J. bras. econ. saúde (Impr.) ; 11(2): 112-118, Agosto/2019.
Artigo em Português | LILACS, ECOS | ID: biblio-1021040

RESUMO

Objetivo: Determinar a factibilidade econômica da técnica de cateterismo central em veia jugular interna guiada pelo ultrassom comparado à técnica-padrão, sob a perspectiva pagadora do Sistema Único de Saúde brasileiro. Métodos: Análise de custo-efetividade utilizando modelo de árvore de decisão sob uma população de pacientes adultos em um cenário de uma unidade terciária. Os custos diretos dos materiais e procedimentos foram estimados utilizando bancos de registros de compras nacionais. Os desfechos foram a ocorrência ou não da punção arterial acidental grave (principal complicação associada ao sítio de punção). Também foram conduzidas análises de sensibilidade determinística e probabilística, bem como curva de aceitabilidade. Resultados: A intervenção onerou o modelo em R$ 53,81. A razão de custo-efetividade incremental calculada foi de R$ 17.936,66 por complicação grave evitada e a curva de aceitabilidade evidenciou que a técnica é custo-efetiva sob uma intenção de pagar de R$ 18.125,00. Na análise de sensibilidade probabilística, 63,6% das simulações mostraram-se custo-efetivas. Conclusão: A intervenção é custo-efetiva, contribuindo para a redução das complicações graves, e o resultado pode proporcionar segurança para tomadas de decisões quanto à padronização do uso da ultrassonografia como orientador do procedimento.


Objective: To determine the economic feasibility of the central catheterization technique in the internal jugular vein guided by the ultrasound compared to the standard technique, under the perspective of the Brazilian Unified Health System. Methods: Cost-effectiveness analysis using decision tree model under a population of adult patients in a tertiary unit scenario. The direct costs of the materials and procedures were estimated using banks of national procurement records. The outcomes were the occurrence or not of severe accidental arterial puncture (the main complication associated with the puncture site). Analyzes of deterministic and probabilistic sensitivity were also conducted, as well as acceptability curve. Results: The intervention cost the model in R$ 53.81. The calculated incremental cost-effectiveness ratio was R$ 17,936.66 due to a serious complication avoided and the acceptability curve showed that the technique is cost-effective under an intention to pay R$ 18,125.00. In the probabilistic sensitivity analysis, 63.6% of the simulations were cost-effective. Conclusion: The intervention is cost-effective, contributing to the reduction of severe complications and the result can provide security for decision making regarding the standardization of the use of ultrasonography as a guideline of the procedure


Assuntos
Humanos , Cateterismo Venoso Central , Ultrassonografia de Intervenção , Avaliação de Custo-Efetividade , Veias Jugulares
3.
Gac. sanit. (Barc., Ed. impr.) ; 33(3): 255-258, mayo-jun. 2019. tab
Artigo em Espanhol | IBECS | ID: ibc-183745

RESUMO

Objetivo: Examinar el apoyo a las guías de publicación para estudios de evaluación económica, como la declaración CHEERS (Consolidated Health Economic Evaluation Reporting Standards), por parte de las revistas biomédicas españolas. Método: Análisis transversal de las normas de autoría de las revistas biomédicas españolas incluidas en Journal Citation Reports 2017. Dos autores examinaron y extrajeron la siguiente información: mención de alguna guía de publicación, declaración CHEERS, recomendaciones del International Committee of Medical Journal Editors (ICMJE) e iniciativa Enhancing the QUAlity and Transparency Of health Research (EQUATOR). Resultados: De las 28 revistas incluidas, 23 (82,1%; intervalo de confianza del 95% [IC95%]: 63,1-93,9%) mencionaron alguna guía. Una única revista mencionó la declaración CHEERS para estudios de evaluación económica. Veinticuatro revistas (85,7%; IC95%: 67,3-96,0%) mencionaron las recomendaciones del ICMJE y 8 (28,6%; IC95%: 13,2-48,7%) la red EQUATOR. La declaración CONSORT (Consolidated Standards of Reporting Trials) para ensayos clínicos fue la guía más mencionada (n=21; 75,0%; IC95%: 55,1-89,3%). Discusión: La mayoría de las normas de autoría no incorporan información sobre cómo presentar evaluaciones económicas. Las revistas deberían apoyar el cumplimiento de las guías de publicación por parte de las personas autoras y revisoras


Objective: To examine the endorsement of reporting guidelines for economic evaluation studies, such as the CHEERS (Consolidated Health Economic Evaluation Reporting Standards) statement, by Spanish biomedical journals. Method: Cross-sectional analysis of the instructions to authors of Spanish biomedical journals included in the Journal Citation Reports 2017. Two authors examined and extracted the following information: mention of any reporting guideline, the CHEERS statement, the recommendations of the International Committee of Medical Journal Directors (ICMJE) and the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) network. Results: Of the 28 journals included, 23 (82.1%; 95% confidence interval [95%CI]: 63.1-93.9%) mentioned at least one reporting guideline in the instructions to authors. Only one journal mentioned the CHEERS statement for health economic evaluations. Twenty-four journals (85.7%; 95%CI: 67.3-96.0%) mentioned the ICMJE recommendations and 8 (28.6%; 95%CI: 13.2-48.7%) mentioned the EQUATOR network. The CONSORT (Consolidated Standards of Reporting Trials) statement for clinical trials was the most- mentioned reporting guideline (n=21; 75.0%; 95%CI: 55.1-89.3%). Discussion: Most of the instructions to authors do not provide guidance on how to report economic evaluations. Journals should support compliance with reporting guidelines by authors and peer-reviewers


Assuntos
Humanos , Avaliação em Saúde/métodos , Publicações Periódicas como Assunto/normas , Autoria/normas , Políticas Editoriais , Estudos Transversais , Publicações Periódicas como Assunto/estatística & dados numéricos , Avaliação de Custo-Efetividade
4.
Radiología (Madr., Ed. impr.) ; 61(2): 153-160, mar.-abr. 2019. tab
Artigo em Espanhol | IBECS | ID: ibc-185125

RESUMO

Objetivo: La utilización de un tapón de hidrogel reduce el número de neumotórax y la necesidad de tubos de drenaje pleural en las biopsias de pulmón guiadas por tomografía computarizada. Realizamos un estudio de coste-efectividad sobre su uso. Material y métodos: Se analizaron 171 biopsias de pulmón divididas en tres grupos: grupo 1 (n=22): punción aspirativa con aguja fina (PAAF) sin tapón de hidrogel; grupo 2 (n=89): PAAF con tapón, y grupo 3 (n=60): PAAF más biopsia con aguja gruesa (BAG) con tapón. Se calcularon costes totales (directos e indirectos) de los tres grupos. Se analizó el porcentaje de diagnósticos correctos, las ratios medias e incrementales y la opción más coste-efectiva. Resultados: Costes totales: grupo 1 = 1.261,28 + 52,65 = 1.313,93 Euros, grupo 2 = 1.201,36 + 67,25 = 1.268,61 euros, grupo 3 = 1.220,22 + 47,20 = 1.267,42 Euros. Porcentaje de diagnósticos correctos: grupo 1 = 77,3%, grupo 2 = 85,4% y grupo 3 = 95% (p = 0,04). Ratio medio de coste-efectividad: grupo 1 = 16,99, grupo 2 = 14,85 y grupo 3=13,34. Conclusiones: El grupo 3 fue la opción dominante, con la menor ratio media, lo cual demuestra que, en las biopsias de pulmón guiadas por TC, la opción más coste-efectiva es la realización de una PAAF y una BAG con la utilización del tapón de hidrogel deshidratado al final del procedimiento


Objective: Using a hydrogel plug decreases the number of cases of pneumothorax and reduces the need for pleural drainage tubes in CT-guided lung biopsies. We aimed to analyze the cost-effectiveness of using hydrogel plugs. Material and methods: We analyzed 171 lung biopsies divided into three groups: Group 1 (n=22): fine-needle aspiration cytology (FNAC) without hydrogel plugs; Group 2 (n=89): FNAC with hydrogel plugs; and Group 3 (n=60): FNAC plus core-needle biopsy (CNB) with hydrogel plugs. We calculated the total costs (direct and indirect) in the three groups. We analyzed the percentage of correct diagnoses, the average and incremental rations, and the most cost-effective option. Results: Total costs: Group 1 = 1,261.28 + 52.65 = euros 1,313.93; Group 2 = 1,201.36 + 67.25 = Euros 1,268.61; Group 3 = 1,220.22 + 47.20 = Euros 1,267.42. Percentage of correct diagnoses: Group 1 = 77.3%, Group 2 = 85.4%, and Group 3 = 95% (p = 0.04). Average cost-effectiveness ratio: Group 1 = 16.99; Group 2 = 14.85; and Group 3 = 13.34. Conclusions: Group 3 was the best option, with the lowest average cost-effectiveness ratio; therefore, the most cost-effective approach is to do FNAC and CNB using a dehydrated hydrogel plug at the end of the procedure


Assuntos
Humanos , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Técnicas de Fechamento de Ferimentos , Biópsia Guiada por Imagem/métodos , Curativos Hidrocoloides , Biópsia por Agulha Fina/métodos , Neoplasias Pulmonares/patologia , Avaliação de Custo-Efetividade , Tomografia Computadorizada por Raios X/métodos , Pneumotórax/prevenção & controle , Estudos Retrospectivos , Sensibilidade e Especificidade
6.
Matronas prof ; 20(2): e27-e35, 2019. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-183296

RESUMO

Objetivo: Analizar la evidencia científica actual sobre las casas de nacimientos (unidades gestionadas por matronas que ofrecen un entorno similar al hogar y promueven la fisiología del parto), en términos de coste-efectividad, satisfacción y seguridad, tanto materna como neonatal, así como el contexto histórico de las mismas en diferentes países y la situación actual de España en relación con el lugar de nacimiento. Material y método: Se realizó una búsqueda en las bases de datos CINAHL, PubMed, Biblioteca Cochrane y Medline, y en las guías clínicas nacionales e internacionales de distintas organizaciones científicas. Resultados: Las últimas evidencias señalan que parir en casas de nacimientos tiene beneficios obstétricos y de coste-efectividad, mayor tasa de partos espontáneos y menor tasa de intervenciones, así como una mayor satisfacción materna. Conclusiones: Parir en casas de nacimientos es una opción segura que ofrece mejores resultados obstétricos para mujeres de bajo riesgo, es más económica y su creación respondería a una demanda social


Objective: To analyse the current scientific evidence about birth centers (units managed by midwives where a homelike environment and promotion of the physiology of birth is offered) in terms of cost-effectivity, maternal satisfaction and safety for mothers and babies, the historical context of birth centers in different countries and the current birthplace situation in Spain. Method: A research was conducted using the databases: CINAHL, PubMed, Cochrane Library and Medline. National and International Clinical Guidelines as well as publications from organisations of scientific interest were also consulted. Results: The latest evidence demonstrates that giving birth in birth centers is associated with obstetric benefits, is more cost-effective, contributes to higher rates of normal vaginal deliveries and less interventions as well as higher levels of maternal satisfaction. Conclusions: Giving birth in birth centers is a safe option that provides better obstetrics outcomes to low risk women, it is more economical and it constitutes a response to a social demand


Assuntos
Humanos , Centros de Assistência à Gravidez e ao Parto/economia , Centros de Assistência à Gravidez e ao Parto/organização & administração , Centros de Assistência à Gravidez e ao Parto/normas , Centros de Assistência à Gravidez e ao Parto/tendências , Medicina Baseada em Evidências , Necessidades e Demandas de Serviços de Saúde/economia , Avaliação de Custo-Efetividade , Apoio Social , Institucionalização/história , Reino Unido , Espanha
7.
Rev. cuba. salud pública ; 44(4)oct.-dic. 2018. tab
Artigo em Espanhol | LILACS | ID: biblio-1042994

RESUMO

Introducción: Estudios de consumo anual, con información de ventas de cigarrillos, permiten monitorear el Programa de Prevención y Control del Tabaquismo de manera costo- efectiva y valorar los resultados alcanzados. Objetivos: Determinar consumo percápita de cigarrillos, estimar precio promedio de la cajetilla de cigarrillos y establecer la elasticidad de la demanda en 2017. Caracterizar la segmentación del mercado según formas de comercialización y describir aspectos económicos y sociales asociados al consumo en ese periodo. Métodos: Estudio convencional, observacional descriptivo, transversal. Resultados: El consumo percápita en la población cubana de 15 años y más fue 1 612 cigarrillos, decreció 2,01 por ciento respecto a 2016. El precio promedio estimado de la cajetilla fue $ 9,90 (moneda nacional), con incremento de 2,06 por ciento y aumento de ventas en pesos cubanos convertibles. Se presenta elasticidad de la demanda de -1,31. Se estima reducción de prevalencia de fumadores en 0,46 por ciento. De 100 cigarrillos vendidos, 26 fueron adquiridos en moneda nacional y 74 en libremente convertible. La marca Criollo se mantiene como líder. Conclusiones: La disminución del consumo percápita de cigarrillos en la población cubana en el 2017 pudiera constituir inicio de tendencia decreciente. El incremento discreto del precio promedio de la cajetilla de cigarrillos resultó suficiente para reducir el consumo. El mercado mantiene preferencia por la marca "Criollo" y a la adquisición de cigarrillos a menor precio. Factores sociales y económicos en el periodo apuntan a ser causa de mayor sensibilidad al precio de los cigarrillos y la reducción de la demanda(AU)


Introduction: Studies of annual consumption including cigarette sales information allow monitoring the Program of Prevention and Control of Smoking in a cost-effective manner and assessing the results achieved. Objectives: To determine the per capita consumption of cigarettes, to estimate the average price of the cigarette package and to establish the elasticity of demand in 2017. To characterize the segmentation of the market according to marketing methods and to describe economic and social aspects associated with consumption in that period. Methods: Conventional, observational, descriptive and transversal study. Results: The per capita consumption in the Cuban population aging 15 years and older was 1 612 cigarettes. It decreased 2.01 percent with respect to 2016. The estimated average price of the pack was $ 9.90 (national currency), a 2.06 percent increase, and increase in sales in Cuban convertible pesos. Elasticity of the demand of -1.31 is exhibited. A 0.46 percent reduction in the prevalence of smokers is estimated. Out of 100 cigarettes sold, 26 were purchased in national currency and 74 in freely convertible. Criollo remains as leader brand. Conclusions: The decrease in per capita cigarette consumption in the Cuban population in 2017 could constitute the beginning of a decreasing trend. The discreet increase in the average price of the pack of cigarettes was enough to reduce consumption. Criollo is still the large selling brand and the community still preferred purchasing cigarettes at a lower price. The price of cigarettes and the reduction in demand point to cause greater sensitivity with regard to the social and economic factors of this period(AU)


Assuntos
Humanos , Masculino , Feminino , Tabagismo/prevenção & controle , Avaliação de Custo-Efetividade , Uso de Tabaco/economia , Prevenção do Hábito de Fumar , Epidemiologia Descritiva , Estudos Transversais , Cuba , Comercialização de Produtos Derivados do Tabaco , Estudo Observacional
8.
Rev. Rol enferm ; 41(11/12,supl): 73-78, nov.-dic. 2018. tab, graf
Artigo em Inglês | IBECS | ID: ibc-179944

RESUMO

Context: Compressive therapy, especially with short-stretch bandage (SSB), is re-commended in the treatment of varicose ulcers, with proved effectiveness in the healing rate or reduction of wound size. However, there is still insufficient evidence of the advantages of this type of therapy in terms of pain, quality of life (QoL) and cost of treatment. Objectives: To compare the effectiveness of SSB with other types of treatments (with or without compression) to improve pain, QoL and cost of the treatment of venous ulcers. Methodology: A systematic literature review (Cochrane methodology) was carried out on PubMed, EBSCO, Scielo, Google Academic, and grey literature. Only experi-mental or quasi-experimental studies, with adults with varicose ulcer were inclu-ded. Two independent reviewers performed critical appraisal, data extraction, and data synthesis. Results: Among 3133 hits screened, 4 randomized controlled trials (RCTs) were in-cluded, including a total of 977 patients. From these 4 trials: 2 analyzed the QoL, without significant differences between SSB and multiple layer compression; 2 showed a trend towards greater reduction of pain with SSB, but without statistically significant difference; 2 studies evaluated the cost of treatment, with contradictory results. It was not possible to perform a meta-analysis due to high heterogeneity. Conclusions: There is no evidence that SSB is more effective than other compression systems in terms of pain, QoL and cost of treatment in people with venous ulcers. More RCT's are needed, using uniform assessment tools, to allow for more robust conclusions, namely through meta-analysis


No disponible


Assuntos
Humanos , Úlcera Varicosa/terapia , Bandagens Compressivas , Manejo da Dor/métodos , Úlcera Varicosa/enfermagem , Avaliação de Custo-Efetividade , Qualidade de Vida , Perfil de Impacto da Doença
9.
Neurocirugía (Soc. Luso-Esp. Neurocir.) ; 29(6): 267-274, nov.-dic. 2018. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-180323

RESUMO

Objetivo: Evaluar los resultados clínicos y angiográficos, así como los costes del tratamiento quirúrgico frente al endovascular, en el tratamiento de los aneurismas incidentales. Material y métodos: Estudio retrospectivo de una serie consecutiva de 89 pacientes de un solo centro tratados endovascularmente (EV) y quirúrgicamente (SC). Se realiza estudio descriptivo de aspectos demográficos (edad, sexo) y de las características de los aneurismas así como se evalúan resultados clínicos (GOS a 6 meses), angiográficos (grado de oclusión) y de costes económicos tanto globalmente como de cada uno de los grupos. Resultados: Ochenta y nueve pacientes tratados entre 2010 y 2015. Un 74% de los pacientes recibieron tratamiento endovascular y un 26% quirúrgico. No hubo diferencias significativas en cuanto a edad o sexo entre los grupos EV y SC. Un 89% de los pacientes presentaron GOS a los 6 meses favorable (4-5), sin diferencias entre ambos grupos. La oclusión completa del aneurisma fue mayor en el grupo SC (96% versus 55%), así como la estabilidad del tratamiento (24% de retratamientos en el grupo EV versus 0% en el grupo SC). Los retratamientos son más frecuentes en aneurismas de circulación anterior (27%) y de mayor tamaño (un 38,5% de los mayores de 10 mm). El gasto en el grupo SC viene derivado fundamentalmente de la estancia hospitalaria en tanto que en grupo EV tiene más importancia el coste de los materiales de embolización. Las estancias medias son notablemente superiores en el grupo SC pero el coste medio del primer ingreso es un 14% superior en el grupo EV debido al precio de los materiales de embolización. El gasto total es notablemente superior en el grupo EV (un 61%) debido a los gastos derivados del seguimiento y de los retratamientos. Conclusiones: Los resultados clínicos de ambos tipo de tratamiento son comparables. El grado de oclusión aneurismática del grupo SC es superior al del EV, así como la estabilidad del tratamiento, precisando menos retratamientos. A pesar de que el tratamiento quirúrgico genera estancias más largas, los costes del grupo EV son notablemente superiores a los del grupo SC debido al precio de los materiales de embolización, el seguimiento que precisan y la tasa de retratamientos. Una adecuada selección de los casos candidatos a coiling o pinzamiento podría mejorar los resultados angiográficos, reducir la tasa de retratamientos y ahorrar costes


Objective: to evaluate the results and costs of surgical treatment against endovascular in non ruptured aneurysms. Material and methods: retrospective study of a consecutive series non ruptured aneurysms from a single-center treated endovascularly (EV) and surgically (SC). A descriptive study of demographic (age, sex) charqacteristics of the patients and the radiological aspects of the aneurysms have been carried out. Clinical results (GOS at 6 months), angiographic data (occlusion classification) and economic costs have been evaluated in both globally, and in each of the groups. Results: 89 patients treated between 2010 and 2015 were reviewed. Most of them were treated endovascularly (74%). There were no statiscally significant differences between EV and SC groups. 89% of the patients presented favourable GOS (4-5) at six months, being this percentage similar in both groups. Complete occlusion was much higher in SC group (96%) than in EV (55%). Retreatment rate was 24% in EV group and 0% in SC group. The retreatments were more frequent in anterior circulation aneurysms and bigger aneurysms (> 10 mm). The expenses in the SC group come mainly from hospital stay, meanwhile in the EV group is due to embolisation materials. The average length of stay (ALOS) are higher in SC group but costs of first admission are higher in EV group (14% more). When the costs of retreatments and follow up are included the costs of endovascular treatment is much higher than the surgical (61% more expensive). Conclusions: results of both types of treatment are comparable. The grade of aneurysmal occlusion of the SC group was higher than the EV, as well as the stability of the treatment, requiring fewer retreatments. Althoug the ALOS in SC group were longer, the costs of the EV group were significantly higher than the SC group due to the costs of embolisation materials, follow up that they need and the rate of retreatment. Adequate selection of candidates for endovascular coiling could improve angiographic outcomes, reduce retraction rates, and save costs


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Procedimentos Endovasculares/economia , Aneurisma/diagnóstico por imagem , Aneurisma/terapia , Achados Incidentais , Hemorragia Subaracnóidea/complicações , Procedimentos Endovasculares/métodos , Aneurisma/economia , Estudos Retrospectivos , Angiografia/economia , Avaliação de Custo-Efetividade
10.
Nefrología (Madrid) ; 38(6): 630-638, nov.-dic. 2018. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-178393

RESUMO

Introducción: La hemodiálisis (HD) progresiva es una modalidad de inicio del tratamiento renal sustitutivo adaptada a las necesidades individuales de cada paciente. Está condicionada fundamentalmente por la función renal residual (FRR). En ella, la frecuencia de sesiones con las que el paciente inicia HD (una o 2 sesiones por semana) es menor que en la HD convencional (3 por semana). Dicha frecuencia aumenta (de una a 2, y de 2 a 3) con el declinar de la FRR. Metodología/diseño: DiPPI es un estudio abierto, multicéntrico, experimental, aleatorizado 1:1 y controlado con procedimiento de práctica clínica habitual, de bajo nivel de intervención y no comercial. Incluye 152 pacientes mayores de 18 años, con enfermedad renal crónica estadio 5, que inician HD como tratamiento renal sustitutivo; y la FRR, medida por aclaramiento renal de urea (KrU) es ≥ 4ml/min/1,73 m2. El estudio se basa en un grupo de intervención con 76 pacientes que iniciarán HD con una sola sesión por semana (modalidad progresiva) y un grupo control con 76 pacientes que comenzarán con 3 sesiones por semana. El objetivo primario es evaluar la supervivencia y los objetivos secundarios son la morbilidad (hospitalizaciones), los parámetros clínicos habituales, la calidad de vida y la eficiencia. Discusión: Este estudio permitirá conocer, con la máxima evidencia científica, cuántas sesiones debe recibir un paciente al inicio del tratamiento con HD, dependiendo de su FRR. Registro: Registrado en U.S. National Institutes of Health, ClinicalTrials.gov con número NCT03239808


Introduction: Progressive haemodialysis (HD) is a starting regime for renal replacement therapy (RRT) adapted to each patient's necessities. It is mainly conditioned by the residual renal function (RRF). The frequency of sessions with which patients start HD (one or two sessions per week), is lower than that for conventional HD (three times per week). Such frequency is increased (from one to two sessions, and from two to three sessions) as the RRF declines. Methodology/Design: IHDIP is a multicentre randomised experimental open trial. It is randomised in a 1:1 ratio and controlled through usual clinical practice, with a low intervention level and non-commercial. It includes 152 patients older than 18 years with chronic renal disease stage 5 and start HD as RRT, with an RRF of ≥ 4 ml/min/1.73 m2, measured by renal clearance of urea (KrU). The intervention group includes 76 patients who will start with one session of HD per week (progressive HD). The control group includes 76 patients who will start with three sessions per week (conventional HD). The primary purpose is assessing the survival rate, while the secondary purposes are the morbidity rate (hospital admissions), the clinical parameters, the quality of life and the efficiency. Discussion: This study will enable us to know, with the highest level of scientific evidence, the number of sessions a patient should receive when starting the HD treatment, depending on his/her RRF. Trial registration: Registered at the U.S. National Institutes of Health, ClinicalTrials.gov under the number NCT03239808


Assuntos
Humanos , Idoso , Insuficiência Renal Crônica/terapia , Avaliação de Custo-Efetividade , Diálise Renal/métodos , Estudos de Casos e Controles , Resultado do Tratamento , Qualidade de Vida
12.
Rev. esp. cardiol. (Ed. impr.) ; 71(12): 1027-1035, dic. 2018. tab
Artigo em Espanhol | IBECS | ID: ibc-179009

RESUMO

Introducción y objetivos: Analizar la razón de coste-efectividad y el impacto presupuestario del tratamiento con evolocumab (inhibidor de la PCSK9) para pacientes en prevención secundaria en el Sistema Nacional de Salud español. Métodos: Se realizaron, desde la perspectiva del sistema sanitario público, análisis de impacto presupuestario, modelos de árbol de decisión y Markov, basándose en el único ensayo clínico con datos de morbimortalidad (FOURIER). Las alternativas comparadas fueron evolocumab frente a estatinas y un 5% ezetimiba conjuntamente. La medida de eficacia utilizada fue el número de eventos cardiovasculares evitados. Se realizaron análisis de sensibilidad univariable y probabilístico. Resultados: El coste sanitario promedio de los pacientes tratados a 26 meses con evolocumab fue de 11.134,78 euros y de 393,83 euros con el estándar (estatinas + ezetimiba). El coste-efectividad incremental superó los 600.000 euros por evento cardiovascular evitado en las 2 variables (primera: muerte cardiovascular, infarto de miocardio, accidente cerebrovascular, hospitalización por angina inestable o revascularización coronaria; segunda: incluye los 3 primeros eventos). A 10 años, el modelo de Markov mostró un coste promedio de 471.417,37 frente a 13.948,45 euros con evolocumab y estándar respectivamente. El tratamiento con evolocumab en hipercolesterolemia familiar supondría anualmente entre 3 y 6,1 millones de euros, lo que supone una diferencia de 2,5-5,1 millones de euros con el tratamiento estándar (2017). Para el año 2021, en hipercolesterolemia no familiar (prevención secundaria), la diferencia osciló entre 204,3 y 1.364,7 millones de euros. Conclusiones: El evolocumab se asocia con menor frecuencia de eventos cardiovasculares, pero resulta ineficiente para los pacientes susceptibles de recibirlo en el Sistema Nacional de Salud


Introduction and objectives: To analyze the cost-effectiveness ratio and budget impact of treatment with evolocumab (PCSK9 inhibitor) for patients in secondary prevention in the Spanish National Health System. Methods: A budget impact analysis, decision tree and Markov models were designed under the public health system perspective, based on the only study with morbidity and mortality data (FOURIER). The alternatives compared were evolocumab vs statins, and dual therapy with ezetimibe in 5% of the population. The measure of effectiveness used was the number of cardiovascular events avoided. Univariate and probabilistic sensitivity analyses were performed. Results: The average annual cost of patients receiving evolocumab was 11 134.78€ and 393.83€ for standard treatment (statins plus ezetimibe). The incremental cost-effectiveness ratio was > 600 000 € per avoided cardiovascular event for both assessed outcomes (first: cardiovascular death, myocardial infarction, stroke, and hospitalization due to unstable angina or coronary revascularization; second: includes the first 3 events). To perform the 10-year Markov model, the average cost of standard treatment was 13 948.45€ vs 471 417.37€ with evolocumab. Treatment with evolocumab for patients with familial hypercholesterolemia would cost between 3 and 6.1 million euros, assuming a difference of 2.5 and 5.1 million euros with the standard treatment (2017). This difference would be between 204.3 and 1364.7 million euros (2021) for those with nonfamiliar hypercholesterolemia (secondary prevention). Conclusions: Treatment with evolocumab is associated with a lower frequency of cardiovascular events, but is inefficient for patients suitable to receive this drug in the Spanish National Health System


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Hipercolesterolemia/tratamento farmacológico , Doenças Cardiovasculares/prevenção & controle , Pró-Proteína Convertase 9/antagonistas & inibidores , Anticolesterolemiantes/uso terapêutico , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Avaliação de Custo-Efetividade , Anticorpos Monoclonais/uso terapêutico , Hipolipemiantes/economia , Anticolesterolemiantes/economia
15.
Online braz. j. nurs. (Online) ; 17(3)sept. 2018. ilus, tab, graf
Artigo em Inglês, Espanhol, Português | LILACS, BDENF - Enfermagem | ID: biblio-1118494

RESUMO

OBJETIVO: Avaliar a viabilidade do tratamento de úlceras venosas com o Plasma Rico em Plaquetas (PRP). MÉTODO: Estudo descritivo do tipo série de casos, realizado como piloto de um ensaio clínico, com amostra de três pacientes, alocados após a randomização, dois para intervenção e um para o controle. O custo direto foi coletado por meio de observação direta. RESULTADOS: Nos pacientes que receberam a intervenção (PRP), das duas úlceras venosas acompanhadas, uma apresentou cicatrização total, com um custo de US$550,35 e a outra obteve taxa de redução de área de 33,33%, com o custo de US$1.070,32. No paciente controle, a taxa de redução da úlcera venosa foi de 83,33%, com o custo de US$361,53. DISCUSSÃO: A partir do teste piloto, foi possível adequar os protocolos e determinar os insumos para realização do estudo. CONCLUSÃO: A avaliação de protocolos clínicos é de suma importância para o desenvolvimento de ensaios clínicos controlados


OBJECTIVE: To assess the viability of the treatment of venous ulcers with platelet-rich plasma (PRP). METHOD: A descriptive case series study conducted as a pilot study for a clinical trial. With a sample of three patients, allocated after randomization, two for intervention and one for control. The cost was collected by means of direct observation. RESULTS: In patients who received the intervention (PRP), two venous ulcers were followed-up, one presented complete healing, with a cost of US$ 550.35, and the other exhibited a rate of area reduction of 33.33%, with a cost of US$ 1,070.32. In the control patient, there was an 83.33% reduction in the venous ulcer area, with a cost of US$ 361,53. DISCUSSION: The pilot test made it possible to adequate the protocols and to determine the supplies required for the completion of the study. CONCLUSION: The assessment of the clinical protocols is pivotal for the development of controlled clinical trials


OBJETIVO: Evaluar la viabilidad del tratamiento de úlceras venosas con el plasma rico en plaquetas (PRP). MÉTODO: Estudio descriptivo de serie de casos, realizado como piloto de un ensayo clínico, con una muestra de tres pacientes, asignados mediante aleatorización, dos para la intervención y uno para el control. El costo directo se estimó mediante observación directa. RESULTADOS: En los pacientes que recibieron la intervención (PRP), de las dos úlceras venosas monitoreadas, una cuales presentó cicatrización total, con un costo de US$ 550,35, y la otra tuvo una tasa de reducción de área del 33,33%, con un costo de US$ 1070,32. En el paciente control, la tasa de reducción de la úlcera venosa fue del 83,33%, con un costo de US$ 361,53. DISCUSIÓN: A partir de la prueba piloto, fue posible adecuar los protocolos y determinar los insumos necesarios para realizar el estudio. CONCLUSIÓN: La evaluación de protocolos clínicos es de suma importancia para el desarrollo de ensayos clínicos controlados


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Avaliação da Tecnologia Biomédica , Úlcera Varicosa , Custos e Análise de Custo , Avaliação de Custo-Efetividade , Plasma Rico em Plaquetas , Insuficiência Venosa , Cicatrização , Ferimentos e Lesões , Hospitais Universitários
16.
Rev. Asoc. Esp. Espec. Med. Trab ; 27(3): 175-181, sept. 2018. tab
Artigo em Espanhol | IBECS | ID: ibc-175367

RESUMO

Para minimizar el riesgo de exposición a sustancias químicas y de infección cruzada entre el paciente y el personal médico, es necesario utilizar medidas de protección individuales, como guantes. De acuerdo con las recomendaciones de los Centros para el Control y la Prevención de Enfermedades (CDC) y la Organización Mundial de la Salud (OMS), siempre se deben usar guantes protectores en caso de contacto con sangre, mucosa, piel lesionada u otro material potencialmente infeccioso asi como contra agentes químicos y medicación peligrosa. Además, los profesionales que trabajan en el sector de la salud deben estar formados en la selección de guantes adecuados para el ejercicio de las actividades asistenciales y en la optimización del uso de guantes en toda la organización de la asistencia sanitaria. Objetivos: el objetivo de esta revisión es estructurar la elección del guante en función del riesgo específico de exposición a agentes médicos físicos, químicos, biológicos y peligrosos. Metodos: la información se basa en una revisión de la literatura científica y experiencias prácticas


To minimize the risk of chemicals exposure and cross-infection between the patient and the medical staff, it is necessary to use individual protective measures such as gloves. According to the recommendations of the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), protective gloves should always be used upon contact with blood, mucosa, injured skin or other potentially infectious materia. In addition, professionals working in the health sector should be guided in the selection of suitable gloves for the exercise of health care activities and in the optimisation of the use of gloves throughout the health care organisation. Objectives: the aim of this review is to structure the choice of glove according to the specific risk of exposure to physical, chemical, biological and dangerous medicinal agents. Methods: the information are based on a review of the scientific literature and practical experiences


Assuntos
Humanos , Luvas Protetoras/normas , Luvas Protetoras , Equipamentos de Proteção/economia , Exposição a Produtos Químicos , Avaliação de Custo-Efetividade , Exposição Ocupacional/prevenção & controle , Roupa de Proteção/normas
19.
Emergencias (Sant Vicenç dels Horts) ; 30(3): 169-176, jun. 2018. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-172957

RESUMO

Objetivo. Evaluar la eficiencia de cinco estrategias diagnóstico-terapéuticas posibles ante la sospecha de intoxicación aguda (IA) por paracetamol (PCT) a través de un análisis coste-efectividad, según la perspectiva del financiador en un hospital universitario terciario dotado de un programa de toxicovigilancia activa validado (SAT-HULP). Método. Estudio de análisis de coste-efectividad (ACE) de cinco alternativas diagnóstico-terapéuticas consideradas en el abordaje de los pacientes atendidos en el servicio de urgencias hospitalario (SUH) con intoxicación por PCT mediante un modelo de árbol de decisión. La población estudiada fueron los pacientes atendidos en un SUH detectados por el SAT-HULP, entre el 1/04/2011 y el 31/01/2015. Las alternativas diagnóstico-terapéuticas consideradas fueron: 1) administración sistemática de Nacetilcisteína; 2) administración del tratamiento según la dosis confirmada; 3) tratamiento según el nomograma de RümackMatthew; 4) tratamiento según test de orina confirmado con posterior test en sangre; y 5) tratamiento según el cálculo de la semivida. Los datos correspondientes a probabilidades fueron obtenidos del programa SAT-HULP y publicaciones sobre la validación de las pruebas diagnósticas. Se realizaron análisis de sensibilidad determinístico y probabilístico. Resultados. Las opciones "Tratar según dosis comunicada" y "Tratar según el nomograma" son las que muestran mejor coste-efectividad. Al compararlas, la razón coste-efectividad incremental es de 5.985,37 Euros para la primera. El análisis de sensibilidad mostró una importante dependencia del modelo a la variación de las variables principales. En el análisis de sensibilidad probabilístico la estrategia "Tratar a todos los casos" respecto a "Cálculo de semivida" obtuvo una razón coste-efectividad incremental de unos 25.111,06 Euros (DE: 1.534.420,16; intervalo: -42.136,03 a 92.358,75), resultando esta última la más eficiente. Conclusiones. La estrategia "Tratar según el nomograma" es la alternativa más eficiente en el diagnóstico y tratamiento de la intoxicacióna aguda por Paracetamol en nuestro medio, no así para un escenario de mayor prevalencia e incertidumbre, donde la opción "Cálculo de semivida" se muestra como la más eficiente


Objective. To evaluate 5 diagnostic-therapeutic strategies for suspected acute paracetamol poisoning in terms of cost-effectiveness in a tertiary university hospital with an active, validated poisoning surveillance program (SAT-HULP). Methods. Cost-effectiveness analysis of the 5 diagnostic-therapeutic alternatives considered when attending patients with suspected paracetamol poisoning. The alternatives were chosen by means of a decision tree. We studied patients detected by the SAT-HULP program between April 1, 2011, and January 31, 2015. The diagnostic-therapeutic alternatives were as follows: 1) systematic treatment of all patients with N-acetylcysteine (NAC), 2) NAC treatment according to the reported dose; 3) NAC treatment according to a Rümack-Matthew nomogram; 4) NAC treatment according to urine test results confirmed by a blood test, and 5) treatment according to elimination half-life calculation. Probability data were obtained from the SAT-HULP program and validation studies corresponding to the diagnostic tests. Deterministic and probabilistic sensitivity analyses were performed. Results. The approaches that were most cost-effective were those guided by reported doses and nomograms. The incremental cost-effectiveness of treatment according to reported dose was Euros 5985.37. The sensitivity analysis showed that the model was highly dependent on variations in the main variables; the probabilistic sensitivity analysis indicated an incremental cost-effectiveness of Euros 25 111.06 (SD, Euros 1 534 420.16; range, Euros 42 136.03-Euros 92 358.75) between the first approach (treat all cases) and last (calculate elimination half-life); half-life calculation was the more efficient. Conclusions. Treating according to nomogram was the most efficient diagnostic-therapeutic approach to treating paracetamol poisoning in our hospital. However, when the prevalence of paracetamol poisoning is higher and uncertainty is greater, it would be more efficient to treat based on calculating the half-life


Assuntos
Humanos , Acetaminofen/envenenamento , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/terapia , Farmacovigilância , Monitoramento de Medicamentos/métodos , Avaliação de Custo-Efetividade , Serviço Hospitalar de Emergência/estatística & dados numéricos , Sistemas de Notificação de Reações Adversas a Medicamentos
20.
Clin. transl. oncol. (Print) ; 20(5): 630-638, mayo 2018. ilus
Artigo em Inglês | IBECS | ID: ibc-173540

RESUMO

Purpose. Management of metastatic disease in oncology includes monitoring of therapy response principally by imaging techniques like CT scan. In addition to some limitations, the irruption of liquid biopsy and its application in personalized medicine has encouraged the development of more efficient technologies for prognosis and follow-up of patients in advanced disease. Methods. PrediCTC constitutes a panel of genes for the assessment of circulating tumor cells (CTC) in metastatic colorectal cancer patients, with demonstrated improved efficiency compared to CT scan for the evaluation of early therapy response in a multicenter prospective study. In this work, we designed and developed a technology transfer strategy to define the market opportunity for an eventual implementation of PrediCTC in the clinical practice. Results. This included the definition of the regulatory framework, the analysis of the regulatory roadmap needed for CE mark, a benchmarking study, the design of a product development strategy, a revision of intellectual property, a cost-effectiveness study and an expert panel consultation. Conclusion. The definition and analysis of an appropriate technology transfer strategy and the correct balance among regulatory, financial and technical determinants are critical for the transformation of a promising technology into a viable technology, and for the decision of implementing liquid biopsy in the monitoring of therapy response in advanced disease


No disponible


Assuntos
Humanos , Biópsia , Oncologia/métodos , Células Neoplásicas Circulantes/patologia , Medicina de Precisão/métodos , Transferência de Tecnologia , Benchmarking , Avaliação de Custo-Efetividade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA